WO2000033837A3 - Myt1 kinase inhibitors - Google Patents

Myt1 kinase inhibitors Download PDF

Info

Publication number
WO2000033837A3
WO2000033837A3 PCT/US1999/028700 US9928700W WO0033837A3 WO 2000033837 A3 WO2000033837 A3 WO 2000033837A3 US 9928700 W US9928700 W US 9928700W WO 0033837 A3 WO0033837 A3 WO 0033837A3
Authority
WO
WIPO (PCT)
Prior art keywords
kinase inhibitors
myt1 kinase
myt1
antagonizing
methods
Prior art date
Application number
PCT/US1999/028700
Other languages
French (fr)
Other versions
WO2000033837A2 (en
Inventor
Maria A Lago
Original Assignee
Smithkline Beecham Corp
Maria A Lago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Maria A Lago filed Critical Smithkline Beecham Corp
Priority to JP2000586329A priority Critical patent/JP2002531500A/en
Priority to EP99968070A priority patent/EP1135126A4/en
Publication of WO2000033837A2 publication Critical patent/WO2000033837A2/en
Publication of WO2000033837A3 publication Critical patent/WO2000033837A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Methods of antagonizing the myt1 kinase receptor are provided.
PCT/US1999/028700 1998-12-07 1999-12-07 Myt1 kinase inhibitors WO2000033837A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000586329A JP2002531500A (en) 1998-12-07 1999-12-07 MYT1 kinase inhibitor
EP99968070A EP1135126A4 (en) 1998-12-07 1999-12-07 Myt1 kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11118398P 1998-12-07 1998-12-07
US60/111,183 1998-12-07

Publications (2)

Publication Number Publication Date
WO2000033837A2 WO2000033837A2 (en) 2000-06-15
WO2000033837A3 true WO2000033837A3 (en) 2000-08-17

Family

ID=22337023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028700 WO2000033837A2 (en) 1998-12-07 1999-12-07 Myt1 kinase inhibitors

Country Status (3)

Country Link
EP (1) EP1135126A4 (en)
JP (1) JP2002531500A (en)
WO (1) WO2000033837A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001237401B2 (en) 2000-03-01 2006-11-09 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP2164846A2 (en) 2007-05-22 2010-03-24 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles and their use as antiviral agents.
WO2015115355A1 (en) 2014-01-31 2015-08-06 カルナバイオサイエンス株式会社 Anticancer agent composition
CN115811976A (en) * 2020-04-01 2023-03-17 修复治疗公司 Methods of using MYT1 inhibitors
WO2024084450A1 (en) * 2022-10-21 2024-04-25 Aurigene Oncology Limited Bicyclic heteroaryl compounds and their derivatives as pkmyt1 inhibitors
WO2024104282A1 (en) * 2022-11-14 2024-05-23 捷思英达控股有限公司 1h-pyrrolo[2,3-b]pyridine derivative, preparation method therefor, and use thereof in medicine
WO2024166131A1 (en) * 2023-02-09 2024-08-15 Satyarx Pharma Innovations Private Limited Heteroaryl compounds as pkmyt1 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946855A (en) * 1987-12-14 1990-08-07 Sawai Pharmaceutical Co., Ltd. Carboxamide derivatives having tetrazole and thiazole rings and their use
JP2000016984A (en) * 1998-03-05 2000-01-18 Pfizer Inc Compound as delta-opioid agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946855A (en) * 1987-12-14 1990-08-07 Sawai Pharmaceutical Co., Ltd. Carboxamide derivatives having tetrazole and thiazole rings and their use
JP2000016984A (en) * 1998-03-05 2000-01-18 Pfizer Inc Compound as delta-opioid agonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS MAW ET AL.: "Preparation of benzylpiperazine derivatives as delta opioid receptor agonists", accession no. STN Database accession no. 132:93337 *
See also references of EP1135126A4 *

Also Published As

Publication number Publication date
WO2000033837A2 (en) 2000-06-15
EP1135126A4 (en) 2003-04-02
EP1135126A2 (en) 2001-09-26
JP2002531500A (en) 2002-09-24

Similar Documents

Publication Publication Date Title
AU4677199A (en) Multibinding inhibitors of topoisomerase
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
AU6998000A (en) Substituted indolinones as tyrosine kinase inhibitors
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
ZA200202985B (en) Tyrosine kinase inhibitors.
AU6471300A (en) P38map kinase inhibitors
AU4956297A (en) Raf kinase inhibitors
AU6230098A (en) Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
AU2563900A (en) Quinoline derivatives as tyrosine kinase inhibitors
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
AU9158498A (en) Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
AU8030598A (en) Indole compounds as cox-2 inhibitors
AU7414300A (en) Method for the production of substituted pyrimidine derivatives
ZA991975B (en) Enzyme inhibitors.
SI0950657T1 (en) Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors
ZA975380B (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors.
AU3944497A (en) 1,2-diarylindole as cox-2 inhibitors
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
AU5391099A (en) Substituted quinazoline derivatives
AU2576501A (en) Protein kinase inhibitors
AU2001241917A1 (en) Myt1 kinase inhibitors
AU3703499A (en) Substituted indolinones as kinase inhibitors
WO2000033837A3 (en) Myt1 kinase inhibitors
AU4685799A (en) Telomerase inhibitors
AU5340698A (en) Novel serine-threonine kinase gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 586329

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999968070

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09857527

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999968070

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999968070

Country of ref document: EP